Atlas Trials

Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma

Clinical trial NCT05600660 · RECRUITING

Trial details

NCT number
NCT05600660
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma
Start date
2022-08-01
Primary completion
2025-12-31
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.